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Abstract 
Polypharmacy, a concurrent chronic use of multiple prescribed and over-the-counter 
medications by the same individual, is one of the clinical problems facing primary care 
providers. Polypharmacy creates the potential for adverse drug-related events, especially 
in the elderly. The advent of electronic medical records (EMR) may help identify and 
respond to these potential adverse events. The purpose of this project was to investigate 
the relationship between the total number of medication taken by elderly, 65 years and 
older, and the severity of drug-drug and drug-disease interactions triggered by the EMR 
system. The study used a retrospective chart review of the EMRs. Three independent 
variables (age, gender, and number of medications) and 4 dependent variables (major 
drug-drug, moderate drug-drug, major drug-drug, and moderate drug-drug interactions) 
were analyzed a sample size of 247 individuals, ranging in age from 65 to 98 years. The 
total number of medications ranged from 2 to 27 medications, with 177 (71.7%) patients 
using 2 to 9 medications, and 70 (28.3%) using 10 or more medications. Correlational 
showed a positive relationship between number of medication and major drug-drug, 
moderate drug-drug, major drug-disease, and moderate drug-disease interactions (r = 
0.240, p = 0.0001; r = .596, p = 0.0001; r = 464, p =0.0001; r = 669, p = 0.0001, 
respectively). However, there was no significant relationship between age and major and 
moderate drug-drug and drug disease interactions. The results of this study contribute to 
positive social change by increasing primary care providers‟ understanding of the role the 
EMR can play in the identification and management of patients with polypharmacy. 
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Section 1: Nature of the Project 
Introduction 
The advent of health information technology (HIT) has played a critical role in 
the advancement of the U.S. health care delivery system and medication safety. However, 
its full potential in improving patients‟ outcomes such as decreasing polypharmacy in 
elderly is yet to be seen as many elderly are still taking too many medications with 
potential adverse events. Decreasing polypharmacy in elderly may not be actualized 
unless there is a change in the prescribing culture of clinicians. To achieve this, 
prescribers need to embrace and meaningfully use the HIT to change a prescribing 
culture that has proven to be harmful to the elderly population. This could be done by 
utilizing the electronic medical record (EMR) automated trigger system. This system is 
one of the HIT innovative capabilities that can assist clinicians at the point-of-care to 
make the best clinical decision in terms of prescription writing based on up-to-date 
information on the EMR. The EMR automated trigger system alerts the providers of the 
potential drug-drug interactions, drug-food interactions, drug-disease interactions, and 
drug-alcohol interactions (eClinicalWorks, 2013). This gives the providers an opportunity 
to review patients‟ medications and discontinue any medication with potential adverse 
drug-drug drug-drug interactions, eliminating potential consequence of polypharmacy at 
the-point-of-care, and enhancing medication adherence and safety. 
 The prevalence and problem of polypharmacy in elderly has been widely 
documented throughout literature. Johnston (2007, p. 259) noted that although “the 
elderly make up less than 15% of the U.S population; they use about 30% of all 
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prescribed medications and 40% of the OTC drugs”. Terrie (2004, p. 1) also reported that 
“Older individuals account for > $3 billion in annual prescription drug sales; 61% of 
elderly are taking one prescription drug, and most of them take an average of 3 to 5 
medications, and nearly 46% of all elderly individuals admitted to hospitals in the United 
States may be taking seven medications”. Adverse drug-related events (ADREs) present a 
challenging and expensive public health problem (Hohl, Dankoff, Colacome, & Afilaloet, 
2001). They account for 3% to 23% of hospital admissions, prolonged hospital stays, and 
increase morbidity and mortality (Classen, Pestotnik, Evans, Lloyd, & Burke, 1997). In 
2001, the National Service Framework for Older People showed that 5% to 17% of 
hospital admissions were caused by adverse reactions to medicines, and 6% to 17% of 
older patients in the hospital experienced adverse drug reactions (Bretherton, Day, & 
Lewis, 2003). Therefore, decreasing polypharmacy should be every provider‟s priority in 
any clinical practice as this will not only promote quality of care for the elderly, but also 
decrease the overall healthcare cost. 
Problem Statement 
The relatively high incidence of polypharmacy in elderly aged 65 years and older 
is one of the clinical problems facing NPs‟ practice in primary care today. Many 
researchers have shown that our elderly patients are receiving several prescriptions from 
different physicians which may increase their risk for adverse drug events (Junius-
Walker, Theile, & Hummers-Pradier, 2007; & Weng, Tsai, Sheu et al., 2013).  Elderly 
patients, because of age, are also known to have multiple or complex illnesses, and are 
often cared for by multiple providers who may not be aware of clinical decisions taken by 
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the other prescribers (Linjakumpu et al., 2002). This can lead to polypharmacy, which in 
turn leads to adverse drug interactions, medication errors, and non-adherence issues 
which are preventable (Linjakumpu et al., 2002).  Furthermore, the problem of 
polypharmacy has since been recognized as the principal medication issue by the United 
States Department of Health and Human services (DHHS) report “Healthy People 2000” 
that medication safety was noted as an objective of the Healthy People 2010 agenda with 
it recommendations including: “close monitoring for adverse medical events, linking 
information systems to prevent errors, having physicians and pharmacists regularly 
review the medications a patient is taking, and counseling the patient about prescriptions” 
(USDHHS, 2000, p.236). Institute of Medicine‟s (IOM, 2006, p. 10) chasm series also 
recommended to health care organizations to “take advantage of the latest information 
technologies” in improving medication safety, hence the significance of this project. This 
project therefore has utilized the EMR automated trigger system to investigate the 
association between the number of medications prescribed and the severity levels of 
drug-drug and drug-disease interactions. The results could then be used to plan 
interventions to decrease polypharmacy and eliminate potential adverse drug-related 
events in elderly. 
Purpose statement and Project objectives 
 The purpose of this project is to investigate the relationship between the total 
number of medication taken by elderly patients 65 years or older and the severity of drug-
drug interactions and drug-disease interactions. The objective of this project is to 
determine if there is a relationship between the number of medications prescribed and the 
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level of severity of these interactions triggered by the EMR. The EMR automated trigger 
system is one of the HIT innovative capabilities which alerts provider of the potential 
drug-drug interactions, drug-disease interaction, drug-food interactions, and drug-alcohol 
interactions. There are two levels of severity of drug-drug interactions and two levels of 
severity of drug- disease interactions triggered by the EMR automated trigger system 
(eClinicalWorks, 2013). These severity levels are major (red color-code) and moderate 
(orange color-code) drug-drug or drug-disease interactions. Hence, the EMR automated 
trigger system categorized the severity level of drug-drug interactions into major drug-
drug interactions (red color-code) and moderate drug-drug interactions (orange color-
code). Similarly, the severity level of drug-disease interactions is categorized into major 
drug-disease interactions (red color-code) and moderate drug-disease interactions (orange 
color-code). This will be discussed in details in Section 3 of this project. 
Project Hypothesis 
The hypothesis of this project is that there will be a positive relationship between 
the number of medications and the number of major severity and moderate severity of 
drug-drug and drug-disease interactions. 
Significance/Relevance to Practice  
One of the major practice issues facing NP practice in primary care is the 
relatively high incidence of polypharmacy in elderly individuals aged 65 years and older. 
Elderly seen in primary care settings come in with multiple prescription, over-the-counter 
(OTC) and herbal medications. Many of these elderly have to rely on their primary care 
providers to review these medications and give them direction on how to self-manage 
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these medications to avoid potential adverse-reactions. Primary care NPs are in a unique 
position to monitor and potentially eliminate adverse effects of a complex medication 
regimen and decrease incidence of polypharmacy in the elderly population by using the 
EMR automated trigger system to eliminate inappropriate and unnecessary medications 
during office visits. The results of this research project will also have effects on nursing-
sensitive outcomes, which will help define guidelines for intervention and prevention of 
ADREs. 
 Swanson (1991, p. 161) defined caring as, "a nurturing way of relating to a valued 
other, toward whom one feels a personal sense of commitment and responsibility" 
Swanson stated that five processes characterize caring: knowing, being with, doing for, 
enabling, and maintaining belief.  Because NPs are an extension of nursing, not medicine, 
NPs practice knowing (empathy), being with (presence), doing for (evidence-based 
practice), enabling (empowerment), and maintaining belief (instilling hope) (Hagedorn & 
Quinn, 2005). Finally because NPs are guided by nursing theory, the success of NPs 
depends on practicing evidence-based care with competency in assessment, diagnosing, 
and managing patients (including writing prescriptions) and maintaining a caring practice 
(Hagedorn & Quinn, 2005). This implies among other measures that NPs meaningfully 
used the available health information technology to prudently write prescriptions to their 
elderly patients. 
Evidence-based Significance of the Project 
 The results of this study will add to the plethora of evidence in managing patients 
with chronic illness who are potentially susceptible to polypharmacy. Evidence-based 
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practice (EBP) is a problem-solving approach for the delivery of healthcare that 
integrates the best evidence from studies and patient care data with clinical expertise and 
patient preferences and values (Fineout-Overholt, 2010). It places emphasis not just on 
best practices but rather on a decision-making process in which decisions are made on a 
case-by-case basis using the best evidence available. Although polypharmacy in elderly 
poses a significant challenge to primary care providers, only three studies reviewed 
associated the number of medications to increase risk of adverse effect. The first study 
was conducted by (Williams, 2002, p. 1917), who reported that “taking only two drugs 
increases the risk of an adverse effect by 6%, eight medications raise risk by 100%”. The 
second study conducted by Goldberg, Mabee, Chan, & Wong (1996, p. 447), found that 
“the probability of an ADR increases from 13% for two drugs to 82% for more than 
seven drugs”. The third study by Frazier (2005, p. 5) reported that “the potential of an 
ADR nears 100% when 10 medications are use”. However, these studies did not specify 
the type or the severity of these interactions. This study will help close the gap in the 
literature and show the association between the total number of medications and type and 
severity of each interaction. According to Rollason & Vogt, (2003, p. 817), 
“polypharmacy in the elderly complicates therapy, increases cost, and is a challenge for 
healthcare agencies”. Pharmacological therapy in the elderly is difficult due to 
physiological changes associated with aging, such as poor absorption and decreased 
metabolism, and these changes may contribute to adverse drug reactions (Trotter, 2001). 
Because the effects of one medication may potentiate or inhibit the action of another 
medication (Fulton & Allen, 2005), polypharmacy complicates drug therapy and needs to 
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be addressed. The utilization of HIT innovative capability, such as the automated trigger 
system, to assist in eliminating inappropriate prescriptions in the elderly population will 
not only reduce potential adverse events, but also reduce overall healthcare cost for this 
population. 
Implications for Social Change 
 The potential benefit of Health Information Technology (HIT) is to increase 
patient safety by minimizing medication errors. Studies have shown that increased safety 
would result mostly from the alerts or triggers or reminders generated by the EHR 
systems for medications (Center for Medicare Advocacy, 2009). These triggers not only 
warn the providers of potential adverse drug interactions with other drugs the patient is 
taking, but also provide recommendations that would prevent such adverse outcomes. 
Rand reports estimated that if hospital used an HIT system with electronic prescribing, 
around 200, 000 adverse drug reactions could be eliminated each year, with annual 
savings of about $1 billion (Center for Medicare Advocacy, 2009). NPs must take 
advantage of the advanced information technology such as electronic prescribing, 
electronic medical records, and electronic laboratory record, and explore ways to use 
them to decrease the risk of adverse drug reactions.  
Electronic script systems are very effective in alerting the providers of potential 
adverse reactions or interactions but this system requires the discipline of the users to 
review them and make the necessary changes based on the alerts recommendations. All 
providers should facilitate and enhance the self-care of all patients, especially the elderly, 
who potentially are the most affected by polypharmacy or excessive prescribing. The key 
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to enhancing self-care and reducing non-adherence include information, instructions, and 
organization. Each office visit should give NPs the opportunity to enhance client‟s self-
care potential by giving appropriate information concerning each prescribed medication, 
such as what the drug is used for, side effects to report, duration of therapy, drug-drug 
interactions, drug-food interactions, and immediate action a client can take in case of 
severe reactions. 
Definition of Terms 
 Polypharmacy: There is no clear definition of polypharmacy throughout the 
literature reviewed, except that it indicates the use of multiple medications 
(prescriptions/OTCs) by a patient. Some definitions of polypharmacy include “excessive 
or unnecessary use of prescription or nonprescription medications” (Jones, 1997, p. 627), 
“use of six or more medications” (Bushardt et al., 2008, p. 383), others consider it as the 
prescription, administration, or use of more medications than are clinically indicated in a 
given patient (Larsen et al., 1999; Montamat and Cusack, 1992). The Center for Medicare 
and Medicaid Services (CMS) defines polypharmacy as treatment with nine or more 
medications. For the purpose of this project, polypharmacy is defined as the concurrent 
chronic use of two or more medications (prescribed/OTCs) by the same individual. This 
definition is appropriate for this study because the EMR automated trigger system 
produces alerts once the clinician enters at least two medications into the patient‟s 
medication record. 
  Electronic Medical Record (EMR): An Electronic Medical Record (EMR), also 
called the Electronic Health Record (EHR) is a digital version of paper charting, which 
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contains links to other databases that assist the providers in diagnosis and treatment, 
referrals to other providers, and billing (CMS, 2013).  
Meaningful Use: Meaningful Use is a term used to set standards or criteria to 
promote the spread of electronic health records and health information in the United 
States. It is a set of standards defined by the Center for Medicare and Medicaid services 
(CMS). The CMS (2013) defines „Meaningful Use‟ as a “set of standards defined by the 
Centers for Medicare & Medicaid Services (CMS) Incentive Programs that governs the 
use of electronic health records and allows eligible providers and hospitals to earn 
incentive payments by meeting specific criteria”.  
Adverse Drug Reactions (ADRs):  The World Health Organization (1992) 
defines adverse drug reaction as “a response to a drug which is noxious and unintended, 
and which occurs at doses normally used in man for the prophylaxis, diagnosis, or 
therapy of disease, or for the modifications of physiological function”.  Edwards and 
Aronson (2000, p. 1256) also defined adverse drug reaction as “an appreciably harmful or 
unpleasant reaction, resulting from an intervention related to the use of a medicinal 
product, which predicts hazard from future administration and warrants prevention or 
specific treatment, or alteration of the dosage regimen, or withdrawal of the product.” 
Limitations 
 This project is limited to one particular primary care office and a single EMR 
system, which may affect the result. Further research needs to be conducted using 
multiple healthcare organizations and EMRs. Sample size may also be a limitation. A 
convenient sample was used which may affect the results. A review of this EMR system 
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during my practicum showed this primary care has over 400 patients 65 years and older, 
however some of these charts will not be used due to inclusion criteria of using only 
charts with two or more medications. 
Summary 
 This section has established the significance of this project to improvement of 
care delivery in primary care settings. The results of this study will lead to health 
promotion of this target population, the elderly, who are the most susceptible to effects of 
polypharmacy. A need to determine the relationship between the total numbers of 
medications prescribed and the severity of drug-drug interactions and other interactions 
will allow nursing researchers to use the results for development of guidelines or tools 
that prescribers can use to eliminate inappropriate or unnecessary prescriptions. Some of 
the recommendations from IOM (2011) report include a call to health care organizations 
to “promote health care that is safe, effective, client-centered, timely, efficient, and 
equitable; that health professionals should be educated to deliver patient-centered care as 
members of an interdisciplinary team, emphasizing evidence-based practice, quality 
improvement, and informatics”. This project is responding to the IOM report by 
attempting to answer this important research question with the hope of using the results to 
promote the health of this target population. 
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Section 2: Background and Context 
Specific Literature Review 
 Electronic Health Records (EHRs) 
The government has developed many policies to promote wider adoption of 
electronic medical records (EMRs) with the hope that they will improve quality of care, 
improve care coordination, and reduce healthcare costs. However, Layman (2008, p. 165) 
noted that research “has not consistently demonstrated access for disadvantaged persons, 
the accuracy of EHRs, their positive effects on productivity, nor decrease costs”. 
Furthermore, Harrington, Kennerly, Johnson, and Snyder (2011, p.31) asserted that 
“While healthcare information technology (HIT) is intended to relieve some of the 
burden by reducing errors, several aspects of the systems such as the electronic medical 
record (EMR) may actually increase the incidence of certain types of errors or produce 
new safety risks that result in harm”. According to CMS (2013) the EHRs “are builds to 
share information with other health providers and everyone involved in patient care and 
patients themselves should be able to access their records at any time to meet the criteria 
for stage one of „meaningful use‟”. This continues to raise concerns regarding safety of 
patients‟ information across a complex health care system as each health organization 
involved in patients‟ care navigate the system to comply with the government regulations 
on the use of EHR. 
 The EMR provides the potential benefits in improving patients quality of care in 
primary care by tracking patients‟ data over time, identifying patients who need 
preventive visits or screening, and monitoring how patients measure up to quality 
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indicators (eClinicalWorks, 2013). It allows patients to access their records. Currently, 
there is a debate in the nation whether patients should be able to edit their medical 
records via the patient portal. Meanwhile, health care organizations continue to rely on 
Health Insurance Portability and Accountability Act (HIPPA) rule which allows patients 
to request that inaccurate information be corrected, but not to demand changes for other 
reasons (USDHHS, 1996).  
  Barriers to full utilization of EMR system include time constraints and lack of 
interoperability of HIT systems. In a study conducted by Houser and Johnson (2008, p.6) 
which aimed at identifying the main barriers to EHRs implementation, they found that 
“the most significant barriers were lack of national information standards and code sets 
(62 %), lack of available funding (59 %), concern about physician (51 %), and lack of 
interoperability (50 %)”. Clinicians in primary care faced a greater challenge in balancing 
efficiency and quality of care. A physician who sees an average of 25 patients a day may 
not have time to review the EMR automated trigger system for recommendations before 
writing a prescription. In a study conducted by Tai-Seale, McGuire, and Zhang (2007, p. 
1871) on “time allocation in primary care office”, they found that “the median visit 
length was 15.7 minutes during elderly patients‟ visits to primary care, and the length of 
visit overall varied little even when contents of visit varied widely” They concluded that 
“a highly regimented schedule might interfere with having sufficient time for patients 
with complex or multiple problems”. Again, in a systemic review study conducted by 
Boostra & Broekhuis (2010) which involved review of 22 previous published studies, 
concluded that physicians cited most often financial barriers, technical barriers, and time 
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constraints as barriers to EHR adoption. Ball, Douglas, and Walker (2011, p 252) also 
reported that “one of the major barriers to EBP is the constraint of time”. Providers are 
constantly under pressure to practice based on current evidence.  However, the 
organizational demand for efficiency does not always allow a clinician to meet both 
demands. This is a major barrier in translating evidence into practice. As Ball et al. 
(2011, p. 247) noted, “access is not usually the prevailing issue; it is the time constraints 
of searching and appraising that become one of the biggest challenges of EBP decision 
making at the point of care”. Providers therefore need to develop strategies to accomplish 
both tasks of practicing based on current evidence and meeting the demand for efficiency. 
 Lack of interoperability may also present a major barrier to full utilization of the 
EMR system. Interoperability is the ability of separate systems to convey information to 
each other in a computer-recognizable format (Ball et al. 2011). Review of this same 
EMR system revealed lack of interoperability with other systems which would have 
increased efficiency. Providers and some pharmacies were still faxing patients‟ records 
which had to be manually retrieved and reviewed by clinicians before attaching it to 
patients‟ charts. This process takes time and delay valuable information that clinicians 
could have used to make the best clinical decision at the point-of-care (Ball et al. 2011). 
Meaningful Use 
 Meaningful use is concerned with capturing the way providers used their EHR, 
comparing it to the measures defined by CMS (eClinicalWorks, 2013). It was meant to 
ensure complete and accurate patients information especially in improving health care 
delivery in the United States. Its aim is to promote the best possible care as providers 
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may be able to access patient health history at the point of care. This was supposed to 
enhance easy information sharing among practitioners, promotes better coordination of 
care, and empowers patients to play more active role in their care and health information 
of self and families. In effect this should potentially improve overall health care quality, 
safety and efficiency through the promotion of health information technology and secure 
health information. The CMS (2013) defines „Meaningful Use‟ as a “set of standards 
defined by the Center for Medicare & Medicaid Services (CMS) Incentive Programs that 
governs the use of electronic health records and allows eligible providers and hospitals to 
earn incentive payments by meeting specific criteria”. Meaningful use is concerned with 
capturing the way providers used their EHR, comparing it to the measures defined by 
CMS (eClinicalWorks, 2013). However, the provider or practice has the option to register 
for attestation for the incentive program on the CMS website. 
 The process involves three stages over a five year period that started in 2011. 
The first stage is data capturing and storage (2011-2012), second stage involves advance 
clinical process (2014) and third stage in 2016 will involve improved outcomes 
(evaluation) (CMS, 2013). The table below shows the three stages of Meaningful Use set 
criteria. 
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Table 1  
 
EHR Incentive Program (CMS.gov, 2013) 
Stage 1:  
Meaningful use criteria focus 
on: 
Stage 2: 
Meaningful use criteria 
focus on: 
Stage 3:  
Meaningful use criteria 
focus on: 
Electronically capturing 
health information in a 
standardized format 
More rigorous health 
information exchange 
(HIE) 
Improving quality, safety, 
and efficiency, leading to 
improved health outcomes 
Using that information to 
track key clinical conditions 
Increased requirements 
for e-prescribing and 
incorporating lab results 
Decision support for 
national high-priority 
conditions 
Communicating that 
information for care 
coordination processes 
Electronic transmission 
of patient care summaries 
across multiple settings 
Patient access to self-
management tools 
Initiating the reporting of 
clinical quality measures and 
public health information 
More patient-controlled 
data 
Access to comprehensive 
patient data through patient-
centered HIE 
Using information to engage 
patients and their families in 
their care 
  
Improving population 
health 
 
General Literature 
Incidence of polypharmacy in the elderly: Many researchers over the years have 
documented on increasing high incidence of polypharmacy in the elderly population in 
the United States. This is not surprising because as the geriatric population continues to 
rise, so does the incidence of polypharmacy. In a study of patients randomly chosen from 
an outpatient clinic at a VA Hospital (primarily a geriatric population), the mean number 
of medications was five, and 65% were taking more than four drugs (Jensen et al., 2002). 
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Another VA study found that 42% of geriatric patients admitted to a facility were taking 
five or more medications (Good, 2002). A study of Swedish elderly found that 39% were 
taking five or more drugs concomitantly (Jorgensen et al., 2001). Again, in a study 
conducted by Steinman et al. (2006), non-institutionalized elderly individuals were found 
to use an average of four drugs, 41% to 65% of elderly individuals used more than four 
drugs daily (Jensen et al., 2002), and elderly individuals receiving home care were found 
to use an average of five and a half medications (Flaherty et al., 2000). In another study 
conducted by Jyrkka et al. (2006) in Finland, the prevalence of polypharmacy (>5 
medicines) increased from 54% in 1998 to 67% in 2003; and excessive polypharmacy 
(>or=10 medicines) also increased from 19% to 28% in the same period. The same study 
also found that persons in institutional care used significantly more medicines (10.9) than 
community-dwelling elderly persons (7.0, p<0.001). Other studies and surveys 
(Routledge et al., 2004; Johnston, 2007) have shown that ambulatory elderly persons fill 
between nine to 13 prescriptions per year; the average prescription per ambulatory 
patients were 5.7 and 7 for nursing home patients; and individuals over age 65 used two 
to six prescription drugs and one to more than three OTC drugs. 
Effects of polypharmacy in the elderly: Many studies have documented several 
negative consequences of polypharmacy. For example, the use of multiple medications 
have been found to increase the risk of medication-related adverse events and drug 
interactions, and creates a more complicated drug regimen for the patient making 
compliance more difficult (Dayer-Berenson & Martinez, 2008). IOM (2006, p.10) 
“concludes that there are at least 1.5 million preventable ADEs that occur in the United 
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States each year”. Other clinical consequences of polypharmacy include non-adherence, 
increased risk of hospitalizations and medication errors (Rollason et al, 2003). In 2001, 
the National Service Framework for Older People showed that 5% to 17% of hospital 
admissions were caused by adverse reactions to medicines and 6% to 17% of older 
patients in the hospital experienced adverse drug reactions (Bretherton et al., 2003). The 
Centers for Education and Research Therapeutics also reports that 100,000 deaths occur 
yearly due to adverse drug reactions, and as the 4
th
 leading cause of death ahead of 
pulmonary disease, diabetes, AIDS, and automobile deaths (FDA, 2008). 
Hohl, et al. (2001) also reported the relationship between polypharmacy, adverse 
drug-related events, and potential adverse drug interactions in elderly patients presenting 
to an emergency department. The result of this study revealed that adverse drug-related 
events (ADREs) account for 10.6% of all emergency department visits, 31% of patients 
had at least one potential adverse drug interaction (PADI) in their medication lists, and 
50% had at least one PADI in their medication list that was unrelated to the ADRE with 
which they presented. The study concluded that ADREs are an important cause of 
emergency department visits in the elderly and PADIs were found in significant 
proportion of medication lists.  
 An increase in the number of medications dramatically increases the number of 
drug combinations, thereby increasing the risk adverse drug reactions (ADRs) and drug-
drug interactions (Jones, 1997). According to the study by Goldberg, Mabee, Chan, & 
Wong (1996, p. 447), “the probability of an ADR increases from 13% for two drugs to 
18 
 
82% for more than seven drugs”. Furthermore, Frazier (2005, p. 5) reported that “the 
potential of an ADR nears 100% when 10 medications are used”. 
Another effect of polypharmacy on the elderly is increased risk for falls. Although 
falls are common occurrences in elderly, one study on the relationship between 
polypharmacy and falls in elderly found that the risk of fall increased significantly with 
the number of drugs used per day. In a univariate analysis, 28 drugs were associated with 
falling (Ziere et al., 2006). The study therefore concluded that fall risk is associated with 
the use of polypharmacy, but only when at least one established fall risk-increasing drug 
was part of the daily regimen. These drugs include diuretics, antiarrhythmics, 
psychotropics, which are prescribed to many elderly patients. 
Polypharmacy may also increase healthcare cost, either from increase in cost of 
unnecessary medications or from the cost of treatment from adverse drug reactions. Visits 
to specialists, emergency care, and hospital admissions contribute to polypharmacy 
because of multiple prescribers and account for an annual cost of $76.6 billion (Prybys et 
al., 2002). Prybys et al. also reported that up to 28% of hospital admissions are secondary 
to an adverse drug event, and the incidence of events in patients over-65 years is more 
than double than in patients 45 years and younger. Sullivan et al. (1992) estimated the 
direct cost of hospitalization due to nonadherence to be $US 85 billion. They also 
suggested that $US 17-25 billion could be attributed to the indirect costs of 
polypharmacy. When polypharmacy is reduced, patients tend to save money. In an article 
on the cost effectiveness of pharmacists‟ drug regimen reviews, Sullivan et al. (2001) 
estimated potential savings resulting from a reduction in medications to be &US 81 
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million a year, saving averted hospitalizations to be $US 224 million annually and 
savings from reduced drug administration time in nursing homes to be $US 154 million. 
The elderly are more at risk of medication errors because of their exposure to a 
greater number of drugs and the complexity of their drug regimen. In a report on 
mortality associated with medication errors, 48.6% of the deaths occurred in patients 
aged over 60 years, and 55% of these patients were taking more than one drug (Phillips et 
al., 2001). 
Factors contributing to polypharmacy in elderly: Researches have shown many 
factors contribute to polypharmacy in elderly. These include age, chronic medical 
condition, self-medication due to direct advertisement to patients, non-compliance/non-
adherence issues, multiple providers, use of multiple pharmacies, excessive prescribing 
culture of some physicians, and lack of care coordination (Good, 2002; Hume, 2005).  
Elderly are prone to chronic medical conditions such as arthritis, hypertension, diabetes, 
heart disease, etc. that necessitate the use of multiple medications. Self-medication has 
increased polypharmacy incidence due to increased direct-advertisement to patients of 
OTCs/Herbal medications (Good, 2002). Prybys et al. (2002) reported that 
complementary and alternative therapies are more popular as demonstrated by a 
significant increase in sales. Patients most often do not consider herbal and OTC 
supplements or remedies as medications and hence do not usually report use of these 
medications to their healthcare providers (Good, 2002). In addition, the elderly 
sometimes have knowledge deficit regarding the medications that they are taking. 
(Linjakumpu et al., 2002, p. 809) reports that “elderly are more likely to have cognitive 
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or sensory disorders that increase the chance of miscommunication with their clinicians 
about how to take their medications and their doses”. This may complicate therapy due to 
non-adherence. 
Aging is also known to increase the risks of medication problems due to chronic 
illnesses such as heart disease, hypertension, diabetes, chronic renal failure and arthritis 
(Veehof et al., 2000). Hence, the symptoms of polypharmacy can be missed or confused 
with another illness making physicians to prescribe more medications instead of 
discontinuing or changing the medication that causes the symptoms in the first place. 
Many authors (Bedell et al., 2000; Kaufman et al., 2002; Linjakumpu et al., 2002; Veehof 
et al., 2000) reported that advanced age was a factor in the development of 
polypharmacy. Furthermore, Veehof et al. (2000) reported that the predictors of 
polypharmacy were (a) numbers of medications at the start of the study, (b) age, (c) 
cardiovascular conditions (i.e. hypertension, coronary ischemic diseases, atrial 
fibrillation, and heart failure), (d) diabetes, (e) stomach disorder, and (f) medication use 
without a clear indication. Hume (2005) reported many patients have multiple providers 
and use more than one pharmacy which creates a situation where neither a single provider 
nor pharmacist knows all the medications prescribed.  
Patient‟s non-adherence or noncompliance to medication therapy increases risk 
for physician to prescribe more medications to treat the same illness leading to 
duplication of medications. The rate of non-adherence has been estimated to be between 
25% and 59% in the elderly and 50% in the aged with chronic conditions (Spina & 
Scordo, 2002). Changes in the drug regimen may be made by patients to increase 
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convenience, reduce adverse effects, or decrease refill expenses. Factors contributing to 
non-adherence include large number of medications, expensive medications, complex or 
frequently changing schedule, adverse reactions, confusion about brand/trade name, 
difficult-to-open containers, limited patient understanding and route of administration 
(rectal, vaginal, subcutaneous , etc.) (Spina and Scordo, 2002). Also, elderly are more 
likely to have cognitive or sensory disorders that increase the chance of 
miscommunication with their clinicians about how to take their medications and their 
doses (Linjakumpu et al., 2002). Elderly may also keep old medications that have been 
discontinued for future use because of cost, but may later start to use these medications 
with the new ones because of cognitive impairment. These contribute to polypharmacy 
which may increase the risk for serious drug interactions and adverse reactions and 
hospitalizations.  
Interventions to reduce polypharmacy in elderly: Health care providers have used 
various methods to assess and decrease the incidence of polypharmacy. These 
interventions include the utilization of the Beers criteria (Beers, 1997), the “brown bag” 
approach (Prybys et al., 2002), using mnemonics such as SAIL or TIDE (Werder & 
Preskorn, 2003), and the “10-step approach” (Carlson, 1996). In 1997, Beers and 
colleagues established criteria to determine inappropriate medications prescribed for the 
elderly and developed a “provider friendly” list to use when determining what medication 
to prescribe for the older client. Example of recommendation in this list is to use 
benzodiazepines in small doses in older individuals because of their increased sensitivity 
to these substances. There is a significant gap in literature of the effectiveness of these 
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interventions. No research was identified that addressed the most effective interventions 
to utilize when decreasing medications, but many researches addressed inappropriate 
prescribing. 
 Prybys et al. coined the term “brown bag syndrome” when clients arrive at the 
emergency room or primary care provider‟s office with a lunch bag filled with various 
prescription and nonprescription medications. It is the providers‟ responsibility to review 
and determine contents of these bags before writing another prescription for these 
patients. Bikowski et al. (2001) recommended the brown bag approach, computerized 
medication regimens, and online communications to decrease medication regimen 
discrepancies. Frequent medication reviews at every visit with the elderly are necessary 
to determine regimen compliance and if medications have been added by another 
provider. Barat et al. (2001) recommended improved patient education (i.e., regarding 
dosage, indication, benefits, risks), the use of “compliance aids” such as pill boxes, 
medication calendars, and careful evaluation of each drug by primary care providers to 
reduce the number of medications prescribed and to increase drug regimen compliance. 
 Werder and Preskorn (2003) advocated the use of the SAIL and TIDE mnemonics 
to avoid polypharmacy. The acronym SAIL represents keeping the prescribed regimen as 
simple as possible, being aware of the potential adverse effects, exploring the indication 
for a prescribed medication, and listing each drug (including name and dosage) on the 
chart and providing a copy to the client. TIDE is another helpful mnemonic for 
prescribers. Werder & Preskorn (2003) identified the importance of scheduling time 
during an office visit to address medications, ensure the prescriber awareness of 
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individual response to medications, avoidance of potential drug-drug interactions, and 
most importantly education of the client. 
 Carlson (1996) advocates the “10-steps to prudent prescribing”. The 10 steps 
include (a) disclosing medication, (b) identifying drugs by generic name and class, (c) 
using the right drug for the right reason, (f) eliminating agents with no benefit, (g) 
eliminating drugs with no indication, (h) substituting a less toxic drug, (i) avoiding cycle 
of “double dipping”, and (j) utilizing the motto of “one disease, one cure, once-a-day”. 
According to Carlson (1996), skillful prescribing habits are beneficial to both the 
provider and the client: side effects of medications can be reduce, drug-drug interactions 
can be avoided, cost effectiveness improved as well as improvement in client compliance, 
and quality of life. 
Polypharmacy, as well as inappropriate prescribing, for the elderly is a major problem 
and a challenge that contributes to costs, adverse drug events, confusion, compliance 
issues, and errors in management. A systematic approach to drug monitoring is an 
important aspect of appropriate prescribing. Attention to prescribing of medications, 
consistent review of medication lists, and reevaluation of indications and outcomes of 
prescribing are essential to ensure that polypharmacy is minimized and safety for patients 
is maximized (Ballentine, 2008). A randomized trial in which residents caring for 
inpatients received a simple medication grid of all the patients‟ medications and times of 
the administration led to a significant decrease in the number of medications in the 
intervention group (Muir et al., 2001). However, despite numerous reports of successful 
interventions to alter prescribing for elderly patients by decreasing either polypharmacy 
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or inappropriate prescribing, there is little evidence documenting an impact on health 
outcomes. Another randomized trial of elderly outpatients at a VA medical center 
involved having a clinical pharmacist meet with intervention patients to make 
recommendations to patients and clinicians concerning drug regimens. Although there 
was a significant decrease in inappropriate prescribing in the intervention group, there 
was no difference in health-related quality of life (Hanlon, et al., 1996). In another report 
of the same trial, investigators found that 26% of drugs stopped as part of the intervention 
(involving nearly one-third of the patients) resulted in adverse drug withdrawal events. 
Unfortunately, approximately one-third of these events resulted in hospitalization, an 
emergency room visit, or an urgent care visit (Graves et al., 1997). 
Despite the plethora of research on polypharmacy, there is still a gap in literature 
on the association between the number of medications taken by elderly and the severity 
of drug-drug interactions. This study will attempt to investigate and answer the research 
question by utilizing the EMR medication automated trigger system to collect data on 
elderly 65 years and older in relation to medication utilization and potential drug-drug 
and drug-disease interactions. 
Conceptual Model 
 The use of conceptual model can be explored to assess how change related to 
implementation of technology can be applied to improve patient outcomes.  To decrease 
polypharmacy through application and meaningful use of HIT innovative capabilities 
such as the automated medication trigger system, Technology Acceptance Model (TAM) 
will be explored. Technology Acceptance Model (TAM) is an information system theory 
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developed by Davis et al. (1989) to show how people come to accept and use technology. 
TAM suggests a number of factors influence people decisions in acceptance of new 
technology, including perceived usefulness, perceived ease of use, subjective norms, 
attitudes and related variables.  Karsh (2004) suggested the use of theoretical models to 
guide and facilitate adoption of health care systems and technologies, citing motivational 
theories such as Maslow‟s needs‟ classification and decision-making theories such as 
Social Cognitive Theory. TAM is based on human factors engineering science, which 
include the study of technology design and evaluation and has been used effectively to 
assess usability and acceptability of technology (Ball, Douglas, & Walker, 2011). 
 Understanding the impact of new technologies on users, organizations, and work 
processes is important (Karsh, 2004). TAM explored the ease of use and usefulness of 
technology which plays a critical role in acceptance. Researchers have identified 
technology characteristic that have a direct and indirect impact on acceptance such as 
response time, flexibility, and breakdown (Karsh, 2004), trust and management support 
(Wu et al., 2008). Although the government policy and incentives ensured the adoption 
and implementation of certified EHR technology, the prescribing culture of some 
clinicians actually does not reflect the meaningful use of this technology. According to 
CMS (2013), meaningful use is a set of standards that will potentially improve overall 
health care quality, safety and efficiency through the promotion of health Information 
Technology and secure health information. However, few researches show the successful 
implementation of this system as it was intended by the government, especially in 
improving the health of the elderly population, which medication management is a major 
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component of health promotion for this population. Although clinicians may have access 
to fully functional EHRs which allows them to translate evidence to practice at point of 
care, its functions are not fully utilized due to time constraint. A familiar culture in 
primary care practice is for a provider to see an average of 25 to 30 patients per day. 
Hence, patients are scheduled every 15 minutes which is not enough time for physician to 
evaluate patient, review chart for any alerts, and review patient‟s current medication in 
order to make the best clinical decision. For example, Tamblyn et al. (1997, p. 430) in a 
study on “unnecessary prescribing of NSAIDs and the management of NSAIDs-related 
gastropathy in medical practice” concluded that shorter visits, especially those less than 
15 minutes, were a risk factor for inappropriate prescribing and management of 
gastrointestinal side effects”. This implies the need for increase visit time for the elderly 
population, who are susceptible to polypharmacy, requiring ample time for physician to 
review their medications at the point-of-care before writing another prescription. 
27 
 
Section 3: Collection and Analysis of Evidence 
Project Design/Methods 
A correlative study design was adopted for this study. A correlative method is 
appropriate for this study because it is non-experimental. According to Polit (2010, p. 
216), “the primary use of correlation procedure is for answering research questions and 
testing hypotheses”. This study is non-experimental and therefore this design is 
appropriate for this study. 
Sampling 
The study sample was collected from one single EMR system used by one 
primary care organization with a total of 497 elderly aged 65 and older. Inclusion criteria 
included patients aged 65 years and older and taking at least two or more medications 
(prescription and OTCs). Exclusion criteria included all patients below 65 years and 
taking zero to one medication. Sample size used was 247 that meet the inclusion criteria 
out of a total of 497 elderly patients. Ethical considerations for collecting research data 
from my clients is the issue of conflict of interest and HIPPA/privacy issues. Chart 
reviews were utilized, removing any identifying information after accessing the EMR 
system to collect data. Although the elderly is the target population, their treatments were 
not altered by this study. 
Data Collection Techniques 
 Created a Data Collection Sheet (Appendix A) 
  Used EMR to select all patients 65 years and older  
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  Manually reviewed the medication records of all selected charts to select charts 
that meet the inclusion criteria to be used in the study and to determine sample 
size. 
  Opened each selected chart to activate each patient medication automated trigger 
system to count and record the number of major drug-drug interactions (red 
color), moderate drug-drug interactions (orange color), major drug-disease 
interactions (red color), and moderate drug-disease interactions (orange color). 
Age, gender, and total number of medications were also obtained.  
Study Variables 
            The study used three independent variables which included number of 
medications, age, and gender. The total number of medications was obtained by counting 
all medications (both OTCs and prescribed) that is on the patient‟s medication list in the 
EMR at the time of data collection. Age was obtained in terms of years and only patients 
65 years and older were included. Gender was obtained as either male or female. 
Dependent variables used included major drug-drug interactions, moderate drug-
drug interactions, major drug-disease interactions, and moderate drug-disease 
interactions. Each color trigger in each category of interaction was assigned the number 
1. All red color triggers under drug-drug interactions category were added to obtain the 
total number of major drug-drug interactions. All orange color triggers under drug-drug 
interactions category were added to obtain the total number of moderate drug-drug 
interactions. Similarly, all red color triggers under drug-disease interactions category 
were added to obtain the total number of major drug-disease interactions. All orange 
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color triggers under drug-disease category were added to obtain the total number of 
moderate drug-disease interactions. Data collection form is included in Appendix A. 
EMR Medication Automated Trigger System 
The EMR medication automated trigger is color-coded to alert prescribers on the 
severity level of drug-drug interactions, drug-disease interactions, drug-food interactions, 
and drug-alcohol interactions. For example, the color red means major drug-drug 
interaction or major drug-disease interaction. The color orange means moderate drug-
drug interaction, or moderate drug-disease interaction, or moderate drug-food interaction, 
or moderate drug-alcohol interaction. Yellow color means minor drug-food interaction, or 
minor drug-alcohol interaction. With these capabilities, this study will attempt to answer 
the research question, and show if there is any relationship between the total number of 
medications the elderly takes and the severity of these interactions. For the purpose of 
this study, drug-food interactions and drug-alcohol interactions triggers were excluded 
from the sample.  
 Tables 2-3 below show a typical alerts triggered by the EMR automated system. 
Not all alerts are included in the tables. A complete list of alerts for this patient, who is on 
14 medications, is seven pages long with one moderate drug-drug interaction, one minor 
(yellow) drug-food interaction, one moderate (orange) drug-food interaction, one 
moderate (orange) drug-alcohol interaction, 28 moderate (orange) drug-disease 
interactions, and 13 major (red) drug-disease interactions. A prescriber may adjust the 
severity of each alert after reviewing the recommendations.  
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Table 2 
Drug-Drug Interactions 
Drug 1 Drug 2 Severity 
Drug To Drug Interaction 
Description 
Adjust 
Severity 
Oxybutynin 
Chloride 
Oral Tablet 
5 MG 
Micro-K 
Oral 
Capsule 
Extended 
Release 10 
MEQ 
Moderate 
Coadministration of Oxybutynin 
Chloride Oral Tablet 5 MG and 
solid dosage forms of potassium 
chloride may increase the risk of 
potassium-induced 
gastrointestinal mucosal damage. 
Coadministration of Oxybutynin 
Chloride Oral Tablet 5 MG and 
solid dosage forms of potassium 
chloride is contraindicated. The 
clinical significance of this 
interaction is unknown. 
Major  
Moderate 
Minor 
Reset  
Source: EMR Automated System Alerts – eClinicalWorks, 2014 
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Table 3 
Drug-Disease Interactions 
Drug Condition Severity Precaution Description 
Lovastatin Oral 
Tablet 40 MG 
Bell's Palsy 
Not 
recommended 
Lovastatin Oral Tablet 40 MG is 
not recommended in Myopathy. 
Since Bell's Palsy is a more specific 
form of Myopathy, the same 
precaution may apply. 
Lovastatin Oral 
Tablet 40 MG 
Facial Paralysis 
Not 
recommended 
Lovastatin Oral Tablet 40 MG is 
not recommended in Myopathy. 
Since Facial Paralysis is a more 
specific form of Myopathy, the 
same precaution may apply. 
Imitrex Oral 
Tablet 100 MG 
Hypertension 
Not 
recommended 
Imitrex Oral Tablet 100 MG is not 
recommended in Hypertension. 
Imitrex Oral 
Tablet 100 MG 
Severe 
Hypertension 
Not 
recommended 
Imitrex Oral Tablet 100 MG is not 
recommended in Hypertension. 
Since Severe Hypertension is a 
more specific form of 
Hypertension, the same precaution 
may apply. 
Imitrex Oral 
Tablet 100 MG 
Moderate to 
Severe 
Hypertension 
Not 
recommended 
Imitrex Oral Tablet 100 MG is not 
recommended in Hypertension. 
Since Moderate to Severe 
Hypertension is a more specific 
form of Hypertension, the same 
precaution may apply. 
Imitrex Oral 
Tablet 100 MG 
Paradoxical 
Pressor Response 
Not 
recommended 
Imitrex Oral Tablet 100 MG is not 
recommended in Hypertension. 
Since Paradoxical Pressor 
Response is a more specific form of 
Hypertension, the same precaution 
may apply. 
Source: EMR Automated System Alerts – eClinicalWorks, 2014 
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Data Collection 
All data were collected from the electronic medical records. Each patient‟s 
medication record was reviewed to collect the number of alerts produced by the EMR 
medication automated trigger system for each severity category of drug-drug and drug-
disease interactions. Again, drug-food and drug-alcohol interactions were not collected. 
Demographic information such as age and gender were also collected. However patient‟s 
name or diagnosis, and other information that may identify the patient were not used 
during data collection in order to protect the human subject and maintain patients‟ 
confidentiality. The IRB approval number for this study is 05-04-15-0381390. 
 
Data Analysis 
Data analysis was performed using Statistical Package for the Social Sciences 
(SPSS) version 18.0.  First, correlation analysis was used to determine the existence of a 
relationship between the dependent variables (major drug-drug interactions, moderate 
drug-drug interactions, major drug-disease interactions, and moderate drug-disease 
interactions) and the independent variables (age and total number of medications). 
Gender, which is a dichotomous variable, was initially included in the analysis by coding 
(female = 0, male = 1) as dummy variable and then excluded from the second analysis. 
Both analyses yielded similar results so I chose to use the second analysis. Finally, a 
multiple regression analysis was used to determine the effect of the independent variables 
on the dependent variables and to test the hypothesis. 
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Summary/Conclusion 
The objective of this study was to determine the relationship between the total 
number of medication taken by the elderly aged 65 and older and the severity of drug-
drug interactions and drug-disease interactions by utilizing the EMR automated trigger 
system which has the capacity to alert clinicians of the severity of these interactions. 
Therefore HIT with it innovative capabilities such as the EMR automated trigger system 
can assist clinicians in eliminating medications with potential adverse events, thereby 
decreasing polypharmacy at the point of care. 
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Section 4: Findings and Recommendations 
Introduction 
This section describes and analyses the data collected and presents the results 
relating to the research hypothesis. A correlation analysis was used to determine the 
existence of a relationship between the dependent variables (major drug-drug 
interactions, moderate drug-drug interactions, major drug-disease interactions, and 
moderate drug-disease interactions) and the independent variables (age and total number 
of medications). Gender which is a dichotomous variable was initially included in the 
analysis by coding (female = 0, male = 1) as dummy variable and then excluded from the 
second analysis. Both analysis yielded similar results, so I chose to use the second 
analysis. Finally, a multiple regression analysis was used to determine the effect of the 
independent variables on the dependent variables and to test the hypothesis. 
 
Results 
Samples: A total of 497 medication records of all patients 65 and older were first 
selected and reviewed from a single EMR system from one primary care office. The 
selected medication records were manually reviewed to select patients‟ medication 
records that met the inclusion criteria to be used in the study. Out of 497 records, 247 
charts met the inclusion criteria and were selected for the study. The final sample size 
was N = 247, which is about 49.7% of the target population. The explanation for the 
remaining 250 records (50.3%) that did not meet the inclusion criteria were mostly 
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patients coming for immigration physical and travel medicine consultations who were not 
required to complete their medication history. 
Demographics: The demographics of the study sample (n = 247) (Table 4) ranged in age 
from 65-98 years. Females (n =179) encompassed 72.5% of the samples. Males (n = 68) 
comprised 27.5% of the sample. Total number of medications used ranged from two-27 
medications, with 177 (71.7%) patients using two-nine medications, and 70 (28.3%) used 
10 or more medications, which is considered excessive polypharmacy. 
Table 4 
 
Sample Demographics 
 
      Number of Sample     Percentage of 
Sample (%) 
            N = 247            N = 247 
________________________________________________________________________ 
Age            65-75                     151         61.1 
            76-86                      73         29.6 
            >86 to 98                     23                      9.3 
  
Gender                Male                      68         27.5 
           Female          179                    72.5 
 
Total # of Med          2-9              177         71.7 
           10 & more                     70         28.3 
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Table 5 
 
Descriptive Statistics for Study Variables   
 
          Variable                    Mean (M)    Standard Deviation (SD)           N 
                                                            
Age of Patients 74.41 7.589 247 
 
Total Number of 
Medications 
 
7.41 
 
5.170 
 
247 
 
Major Drug-Drug 
Interactions 
 
0.40 
 
1.139 
 
247 
 
Moderate Drug-Drug 
Interactions 
 
1.83 
 
2.687 
 
247 
 
Major Drug-Disease 
Interactions 
 
1.34 
 
3.344 
 
247 
 
Moderate Drug-
Disease Interactions 
 
 
18.77 
 
 
28.220                            
 
 
  247 
 
 
 
A summary of the descriptive statistics for the study variables is shown above. 
Age of patients studied ranged from 65 to 98 years (M= 74.41, SD= 7.6) (Tables 4 and 
5). Total number of medications taken by patients ranged from 2-27 (M=7.41, SD= 
5.170) (Tables 4 and5). The highest number of interactions produced by the EMR 
automated trigger system came from moderate drug-disease interactions (M= 18.77, SD= 
28.220) (Table 5). Major drug-drug interactions has the lowest number of interactions 
(M= 0.40, SD= 1.139) (Table 5). Moderate drug-drug and major drug-disease interactions 
were closed in the number of interactions produced (M= 1.83, SD= 2.687 and M= 1.34, 
SD= 3.344, respectively) (Table 5). 
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Table 6 
 
Summary of Correlations Analysis of Independent Variables and Dependent Variables 
(N=24) 
 
Independent                  Dependent                                  Pearson r                     p-value 
Variables                       Variables                                                                         
_______________________________________________________________________ 
         
Age                           Major drug-drug                               -.032                             .620 
Total # of Med          Major drug-drug                                .240                             .000** 
 
Age                            Moderate drug-drug                          -.059                            .357  
Total # of Med           Moderate drug-drug                           .596                            .000** 
 
Age                            Major drug-disease                            .039                            .543 
Total # of Med           Major drug-disease                            .464                            .000** 
 
Age                            Moderate drug-disease                       -.054                            .398 
Total # of Med           Moderate drug-disease                       .669                         .000**   
_______________________________________________________________________            
**. Correlation is significant at the 0.01 level (2-tailed).   
*. Correlation is significant at the 0.05 level (2-tailed). 
 
The Pearson correlation statistics revealed that as the number of medication 
increased, major drug-drug, moderate drug-drug, major drug-disease and moderate drug-
disease interactions also increased (r = 0.240, p = 0.000; r = .596, p = 0.000; r = 464, p 
= 0.000; r = 669, p = 0.000, respectively). Therefore, the findings are significant. The 
Pearson correlations (r = -0.032, -0.059, 0.39, -0.054) do not depict significant 
relationship between age and major drug-drug, moderate drug-drug, major drug-disease, 
and moderate drug-disease interactions (table 6). 
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Table 7 
Summary of Regression Analysis Using Age and Total Number of Medications as Independent Variables 
and Major drug-drug, Moderate drug-drug, Major-drug disease, and Moderate drug-disease as Dependent 
Variables.  
 
 
 ANOVA 
MODEL 
Sum of 
Squares 
df Mean 
Square 
F Sig.  R R
2
  Adj. 
R
2
 
Std. 
Error 
of 
Est. 
Major 
Drug-
Drug 
Regression           18.906           2 9.453     7.678     .001  .243 .059 .051 1.110 
Residual            300.414        244 1.231       
Total            319.320        246        
Mod. 
Drug-
Drug 
Regression         640.661               2 320.305     68.823     .000  .601 .361 .355 2.157 
Residual            1135.584        244 4.654       
Total            1776.194        246        
Major 
Drug-
Disease 
Regression 594.546      2 297.273 33.629 .000 .465 .216 .210 2.973 
Residual 2156.887 244 8.840       
Total 2751.433 246        
Mod. 
Drug-
Disease 
Regression 88755.286 2 44377.64 101.05 .000 .673 .453 .449 20.96 
Residual 107157.094 244 439.168       
Total 195912.381 246        
           
 Coefficients Unstandardized 
Coefficients 
Standardized 
Coefficients 
  
B Std. 
Error 
    Beta T Sig. 95% 
CI  LB 
for B 
95% 
CI 
UB 
for B 
  
Major 
Drug-
Drug 
(Constant) .439 .702  .625 .533 -.944 1.821   
Total No. of                                     
medications 
.053 .014 .241 3.885 .000 .026 .080   
Age of 
Patient        
-.006 .009 -.039 -.623 .534 -.024 .013   
Mod. 
Drug-
Drug 
(Constant) 1.535 1.365   1.125 .262 -1.153 4.223   
Total No. of                                       
medications 
.311 .027 .598 11.676 .000 .258 .363   
Age of 
Patient        
-.027 .018 -.076 -1.486 .139 -.063 .009   
Major 
Drug-
Disease 
(Constant) -1.718 1.881   -.914 .362 -5.423 1.987   
Total No. of                                   
medications 
.300 .037 .463 8.172 .000 .228 .372   
Age of 
Patient        
.011 .025 .026 .450 .653 -.038 .060   
Mod. 
Drug-
Disease 
(Constant) 11.903 13.26 
  
.898 .370 -14.21 38.02   
Total No. of                                 
medications 
3.664 .259 .671 14.170 .000 3.154 4.173   
Age of 
Patient        
-.273 .176 -.073 -1.549 .123 -.620 .074   
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In the regression analysis summary (Table 7), the effects of independent 
variables on the dependent variables are summarized. The number of medications 
explains only 5.9 % (r²= .059) of the variations in the major severity level of drug-drug 
interactions. This result was unexpected because 94% of the variation in major drug-
drug interactions cannot be explained by the total number of medications. Total number 
of medications is significant at (p =0.001). Age was not significant. For beta 
coefficients, the total number of medications is nearly six times as much weight as age 
in predicting major drug-drug interactions. The number of medications also explains 
36.1% (r²= .0361) of the variations in the moderate severity level of drug-drug 
interactions. The number of medications was significant at p-value of 0.000. Age was 
not significant. Like major drug-drug interactions, moderate drug-drug interactions are 
not significantly related with age. In comparing beta coefficients, the total number of 
medications has eight times as much weight on moderate severity of drug-drug 
interactions as age. The number of medications also explains only 22.0% (r²= .216) of 
the variations in the major severity of drug-disease interactions. Total number of 
medications was significant at p-value of 0.000. Beta values, or in comparing 
coefficients, the total number of medications is nearly 18 times a stronger predictor than 
age. That means total number of medications has 18 times as much weight or impact as 
age in predicting moderate severity of drug-disease interactions. The number of 
medications explains nearly 45.3% (r²= .453) of the variations in the moderate severity 
level of drug-disease interactions. Like other interactions in the sample, the total number 
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of medications is significant predictor of moderate drug-disease interactions. In 
comparing the coefficients, total number of medications has nine times as much weight 
as age in predicting moderate severity level of drug-disease interactions. 
Discussion 
The results of the analysis consistently revealed a positive correlation between the 
number of medications and the severity levels of drug-drug or drug-disease interactions. 
Correlation statistics revealed that as the number of medication increased, the severity 
level of each interaction increased. The number of medications had the strongest effect on 
moderate drug-drug and moderate drug-disease interactions, explaining 36.1% (r²= 
.0361) and 45.3% (r²= .453) of the variations respectively. However, while the total 
number of medications did have a positive correlation with major drug-drug/drug-disease 
interactions, the effects were not very strong, explaining only 5.9% (r²= .059) and 22.0% 
(r²= .216) of the variations respectively.  
 Other independent variable (age) showed no relationship with all severity 
levels of drug-drug and drug-disease interactions throughout the analysis. This was 
unexpected because according to previous study, advanced in age increases the potential 
of drug-drug interactions due to age physiologic changes (Cusack, B.J., 2004). Since 
positive correlation in the analysis is only seen between the number of medications and 
all severity levels of drug-drug and drug-disease interactions, the hypothesis that there 
will be a positive relationship between the number of medications and the number of 
major severity and moderate severity of drug-drug and drug-disease interactions is 
accepted. 
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The findings of this study are similar to other previous studies which associated 
an increase in the number of medications taken by elderly to an increase in drug-drug 
interactions. For example, three studies found associated the increase number of 
medications to increase risk of adverse effect or drug-drug interactions. The first study 
conducted by (Williams, 2002, p. 1917) concluded that “taking only two drugs increases 
the risk of an adverse effect by 6%, eight medications raise risk by 100%”. The second 
study conducted by Goldberg, Mabee, Chan, & Wong (1996, p.447), found that “the 
probability of an ADR increases from 13% for two drugs to 82% for more than seven 
drugs”. The third study by Frazier (2005, p. 5) reported that “the potential of an ADR 
nears 100% when 10 medications are use”. Although these studies only examined the 
relationship between the number of medications and drug-drug interactions without 
looking at the severity levels of these interactions, they at least pointed to the same 
conclusion that an increase in the number of medication prescribed is associated with an 
increase in adverse drug-drug interactions. This study has therefore expanded on this 
knowledge by looking at the association between the number of medication and the 
severity of these interactions and concluded that there is a significant positive correlation 
between the number of medications taken by elderly and the severity levels of drug-drug 
and drug-disease interactions. 
The results of this study also revealed that increase in number of medications does 
not always result in increase in drug-drug/drug-disease interactions. A number of unusual 
cases in the data showed the existence of polypharmacy without any or very few 
corresponding increase in the number of various interactions as one would expect 
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(Appendix B). For example, a 76 y/o female with 10 medications and a 75 y/o female 
with eight medications resulted in zero alerts which mean zero drug-drug and zero drug-
disease interactions (Appendix B). This raises an important clinical question whether the 
class of drug combination may be responsible for drug-drug/drug-disease interactions and 
not always the number of medications taken. Studies have shown that certain classes of 
drugs more than others often cause adverse reactions in the elderly (Nobel, 2001). Such 
drugs include but not limited to psychotropics, anti-hypertensives, diuretics, nonsteriod 
anti-inflammatory drugs (NSAIDS), and corticosteroids, as well as particular drugs, such 
as digoxin and warfarin (Nobel, 2001). Other drugs to be taken with caution by elderly 
include anti-cholinergic and sedative/hypnotic agents (may cause changes in mental 
status), OTC sleep /cold remedies such as Benadryl,  H2 receptor antagonists (ranitidine), 
and beta blockers (atenolol) as they may cause confusion in elderly (Dayer-Bereson 
&Martinez, 2008). This therefore revealed the need for exploration of the implications of 
the study. 
Implications 
This study showed no relationship between age and the various severity levels of 
drug-drug/drug-disease interactions as one would expect and as found in literature. 
Therefore further research is needed to explore why no relationship exist between age 
and drug-drug/drug-disease interactions in elderly population aged 65 years and older. 
Another profound result of this study that needs further research is the existence of 
polypharmacy without any corresponding increase in drug-drug/drug-disease interactions.  
Polypharmacy in elderly has remained a major problem for NP practice. Therefore, the 
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ability to utilize health information technology to determine the association between the 
number of medications and the severity of drug-drug and drug-disease interactions should 
guide the NP in quality improvement initiative planning that will chart the course of 
change in the way providers prescribe to this population. The process of completing this 
study has also exposed some organizational factors such as time constraint and demand 
for efficiency that sometimes act as barriers to full utilization of the available health 
information technology (HIT) in improving quality of care. These two factors require an 
organizational approach and a transformative leadership to chart the course for change.  
Recommendations 
NP practice should ensure full utilization of the EMR automated trigger system 
which has the capability of alerting prescribers of potential drug-drug and drug disease 
interaction. Since this study has shown that polypharmacy does not always result in drug-
drug/drug-disease interactions, implementation of initiative to examine the evidence 
relating to the effect of drug class on potential interactions is needed. As time constraint 
continues to present a major barrier to full utilization of EMR automated trigger system at 
the point of care, an evaluation of the usefulness of existing toolkit and development of a 
toolkit to assist prescribers to know which classes of medications to be eliminated in 
elderly or which combination of medications that should not be prescribed to this 
population is recommended.  Every NP in primary care with HIT should lead in 
evaluation of the EMR automated trigger system to determine classes of medications that 
caused the alerts and review the evidence-based recommendations to determine safer 
alternatives. NP collaboration with physician, pharmacy, and other stakeholders in 
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designing any clinical tool that will assist clinicians to stop or change medications with 
potential adverse events when prescribing for elderly will ensure sustainability of such 
initiative. Primary care providers should find a way to utilize the available clinical tools, 
such as the BEERS, STOPP and START criteria, and to incorporate these criteria into the 
toolkit, which can be used as part of orientation to the EMR system utilization for newly 
hired providers. The targeted class of medications should be those that trigger major 
drug-drug or major drug-disease interactions to eliminate or not start them on elderly. 
Safer alternatives should also be created for these classes of medications if they cannot be 
avoided. These should be available to providers inside the toolkit so that it will eliminate 
time the providers could have used to search for alternatives before prescribing.  
 In order to overcome some of the usability challenges facing health information 
technology implementation, NPs should be aware of the principles of HIT usability so 
that they can give input in the design selection, testing, training end user, and 
implementation process where it affects end users and patient care. Before any system is 
selected, the clinicians should be involved early in the project with system requirements 
development and system selection.  
 Primary care NPs should explore the potential benefits of  increase in visit time 
from 15 minutes to 30 minutes for elderly population to give the providers ample time to 
review patient‟s medications, review the EMR automated trigger system for any potential 
drug-drug or drug-disease interactions, and review evidence-based recommendations 
before writing medications for the elderly. NP should take the leadership role in 
implementing these changes as they are in a unique position to provide leadership in the 
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evaluation of the health information system to determine how to use it to eliminate 
inappropriate prescribing. This may involve employing collaborative and leadership skills 
to create change in the prescribing culture of clinician that has proven to be detrimental to 
the elderly population.  
 
Strength and Limitations 
 
Strength: The significance of this project is the ability to cause improvement of care 
delivery in primary care settings. This project has led to evaluation of this organization‟s 
current EMR system for the first time. The evaluation exposed system failure which has 
therefore resulted in two ongoing quality improvement initiatives: increase in office visit 
time for elderly from 15 to 30 minutes and the development of a toolkit to assist 
clinicians eliminate inappropriate and unnecessary prescription at the point of care. In 
moving forward, the goal is to achieve a total practice transformation through HIT 
application by meaningfully using the evidences that are already there to produce a better, 
safer, more efficient, cost effective care to the elderly population. 
Limitations: This project is limited to one particular primary care office and a single 
EMR system, which may affects the result. Therefore, further research needs to be 
conducted using multiple healthcare organizations and EMRs. Sample size may also be a 
limitation. A small sample size was used which may affect the results.  
Analysis of Self  
As scholar: The process of completing this project has allowed me to develop as a 
scholar through the tedious and elaborate process that causes one to engage in 
development of a final project (Capstone). This process exposed me to important areas of 
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being a successful DNP scholar which involve critical analysis, synthesis of literature, 
and application of theory and research to nursing-practice problem in any practice setting. 
At the completion of this process, I can truly see how much I have grown and actually 
embrace research as part of my continuous education goals. Since the inception of the 
program, I have gotten involved in collection of data from my practice for our nursing 
organizations and colleagues who are engaged in one research project or the other. I have 
also mapped out plan to continue this project as future goals after graduation. 
As practitioner: The DNP project process and the DNP program as a whole as increased 
my skills as a clinician. Practicing based on evidence is no longer optional for me but an 
obligation I have since cultivated in order to provide my patients the best possible care. 
One example of this development is in the area of health information system application. 
Before the start of this program, the electronic health record system was nothing but 
another tool I thought was given to us to increase our workload. However, through the 
practicum experience I soon discovered how much we have missed in not fully utilizing 
and meaningfully using the EMR system as it was intended. The exposure through the 
DNP project/practicum process has led to not only evaluation of this system for the first 
time since its inception, but also exposure to the flaws in the system. This in turn led to 
the development of two ongoing quality improvement initiatives that if successfully 
implemented have the potential to produce a better, safer, more efficient, cost effective 
care to the elderly population. 
As Project developer: The process of conducting a DNP project has increased my 
knowledge in the areas of need assessment, strategy mapping, data collection and 
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analysis.  Methodology that was used in conducting need assessment for decreasing 
polypharmacy in elderly included using resource inventories. This involved mapping 
strategy to gather all information to identify every agency or stakeholder that provided 
services directly or indirectly to this population such as the pharmacists, specialists, home 
health agencies, EHR vendors. This progress therefore increased my communication and 
leadership skills which was helpful in getting my organization embraced change which 
would ultimately improve outcomes for this target population. 
What does this Project mean for future professional development? 
The experience gained from this project has opened my vision about future 
projects and research work that I planned to embark on in the future. With the DNP 
preparation, I now have a firm grasp of how to be a catalyst for change which is required 
in our fast changing health care delivery system. As the nation‟s healthcare delivery 
system changes, so is the demand on DNP- prepared nurses who are in a unique position 
to rethink and re-evaluate many processes in both micro and macro levels, plan and 
implement interventions that would not only impact the system positively but also lead to 
improve patient outcomes.  
Summary and Conclusion  
The findings of this study are similar to other studies revealing the association 
between increased number of medications and drug-drug/drug-disease interactions. This 
study has added to research knowledge on polypharmacy by showing a positive 
correlation between the number of medications and the severity level of each interaction. 
Therefore, health information technology with its innovative capabilities such as the 
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EMR automated trigger system potentials in decreasing medication errors, increasing 
safety, improving care coordination may not be realized until healthcare organizations 
fully take advantage of its capabilities and meaningfully use it at the point of care as it 
was intended. With the capability of the EMR automated trigger system in alerting 
prescribers of the potential drug-drug, drug-disease, drug-food, and drug-alcohol, a 
prescriber therefore can utilize its evidence-based recommendations in prescribing safely 
thereby eliminating drug combinations with potential adverse drug interactions. 
The following clinical tools are also available in assisting providers in reducing 
the risk of drug-drug interactions: The BEERS, STOPP and START criteria. The Beers 
criteria are accessible on the American Geriatrics Society website at 
http://www.americangeriatrics.org. They can also be printed as a pocket card and 
downloaded as a smartphone app by providers to be used at the point of care. The STOPP 
criteria are designed to be used in tandem with the START (screening tool to alert 
doctors to right treatment criteria (Ryan, O‟Mahony, Kennedy, Weedle, & Byrne, 2009). 
Both are available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810806/. 
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Section 5: Scholarly Product 
A Project Summary and Evaluation Report 
Title 
 
Polypharmacy, the Electronic Medical Record, and Adverse Drug Events 
Introduction  
The advent of health information technology (HIT) has played a critical role in 
the advancement of the U.S. health care delivery system and medication safety. HIT has 
the potential to improve medication safety and decrease adverse drug events in elderly 65 
years and older who are at risk for polypharmacy. Decreasing polypharmacy needs 
utilization of HIT innovative capability, EMR automated trigger system at the point-of- 
care. The EMR automated trigger system alerts the providers of the potential drug-drug 
interactions, drug-food interactions, drug-disease interactions, and drug-alcohol 
interactions. There is increased in use of electronic medical records in the U.S. since the 
introduction of the government incentive money, although still behind other developing 
nations like the Netherland and United Kingdom (Figure 1). 
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Figure 1 
 
One of the major practice issues facing NP practice in primary care is the 
relatively high incidence of polypharmacy in elderly individuals aged 65 years and older. 
Elderly seen today in primary care settings come in with brown bags or grocery bags full 
of not just prescription medications, but also over-the-counter (OTC) and herbal 
medications. Many of these elderly have to rely on their primary care providers to review 
these medications and give them direction on how to self-manage these medications to 
avoid potential adverse-reaction. Primary care NPs are therefore in a unique position to 
monitor and potentially eliminate adverse effects of a complex medication regimen and 
decrease incidence of polypharmacy in the elderly population by taking advantage of the 
EMR automated trigger system to eliminate inappropriate and unnecessary medications 
during office visits. 
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 The purpose of this project therefore was to investigate the relationship between 
the total number of medication taken by elderly 65 years and older and the severity of 
drug-drug interactions and drug-disease interactions using the EMR automated trigger 
system. There are two levels of severity of drug-drug interactions and two levels of 
severity of drug-disease interactions as triggered by the EMR automated trigger system. 
These severity levels are color-coded as: major (red color-code) and moderate (orange 
color-code) drug-drug or drug-disease interactions (Figure 2). 
  
Figure 2: Drug-Drug Interaction Triggers 
 
Literature Review 
The relatively high incidence of polypharmacy in elderly aged 65 years and older 
is one of the clinical problems facing NPs‟ practice in primary care today. Many 
researches have shown that our elderly patients are receiving several prescriptions from 
different physicians which may increase their risk for adverse drug events (Weng, Tsai, 
Sheu et al., 2013; Junius-Walker, Theile, & Hummers-Pradier, 2007). “The elderly make 
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up less than 15% of the U.S population; they use about 30% of all prescribed medications 
and 40% of the OTC drugs” (Johnston, 2007, p.259). “Older individuals account for > $3 
billion in annual prescription drug sales; 61% of elderly are taking one prescription drug, 
and most of them take an average of 3 to 5 medications, and nearly 46% of all elderly 
individuals admitted to hospitals in the United States may be taking seven medications” 
(Terrie, 2004, p.1). Adverse drug-related events (ADREs) present a challenging and 
expensive public health problem (Hohl et al., 2001). They account for 3% to 23% of 
hospital admissions, prolonged hospital stays, and increase morbidity and mortality 
(Classen et al., 1997). Other clinical consequences of polypharmacy include non-
adherence, increased risk of hospitalizations and medication errors (Rollason et al., 
2003).  
 Institute of Medicine (IOM, 2006, p.10) chasm series also recommended to health 
care organizations to “take advantage of the latest information technologies” in 
improving medication safety, hence the significance of this project. Studies have shown 
that increased safety would result mostly from the alerts or triggers or reminders 
generated by the EHR systems for medications (Center for Medicare Advocacy, 2009). 
Rand reports estimated that if hospital used an HIT system with electronic prescribing, 
around 200, 000 adverse drug reactions could be eliminated each year, with annual 
savings of about $1 billion (Center for Medicare Advocacy, 2009).  
Methodology  
This study required an IRB approval which was obtained before data collection. A 
correlative study design was adopted for this study. Data collection was done in one 
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primary care setting with over 400 elderly patients 65 years and older with a single EHR 
system. Inclusion criteria included all elderly 65 years and older taking two or more 
medications (prescribed/OTC). A total number of medication records that met the 
inclusion criteria were 247. A data collection form which included three independent 
variables: number of medications, age and gender; and four independent variables: major 
drug-drug interactions, moderate drug-drug interactions, major drug-disease interactions, 
and moderate drug-disease interactions was created and used in recording the data. All 
data were collected from the patients‟ electronic medication records after removing 
patient‟s identifiers such as name, address, and diagnosis in order to protect the human 
subject and maintain patients‟ confidentiality. The number of alerts produced by the 
EMR medication automated trigger system for each severity category of drug-drug and 
drug-disease interactions was obtained.  
 Data analysis was performed using Statistical Package for the Social Sciences 
(SPSS) version 18.0. First, correlation analysis was used to determine the existence of a 
relationship between the dependent variables (major drug-drug interactions, moderate 
drug-drug interactions, major drug-disease interactions, and moderate drug-disease 
interactions) and the independent variables (age and total number of medications). 
Gender which is a dichotomous variable was initially included in the analysis by coding 
(female = 0, male = 1) as dummy variable and then excluded from the second analysis. 
Finally, a multiple regression analysis was used to determine the effect of the 
independent variables on the dependent variables and to test the hypothesis. 
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Results 
 
Table 6 
Summary of Correlations Analysis of Independent Variables and Dependent Variables 
(N=247) 
Independent                  Dependent                                  Pearson r                     p-value 
Variables                       Variables                                                                         
_______________________________________________________________________ 
         
Age                           Major drug-drug                               -.032                             .620 
Total # of Med          Major drug-drug                                .240                             .000** 
 
Age                            Moderate drug-drug                          -.059                            .357  
Total # of Med           Moderate drug-drug                           .596                            .000** 
 
Age                            Major drug-disease                            .039                            .543 
Total # of Med           Major drug-disease                            .464                            .000** 
Age                            Moderate drug-disease                       -.054                            .398 
Total # of Med           Moderate drug-disease                       .669                            .000**   
________________________________________________________________________          
**. Correlation is significant at the 0.01 level (2-tailed).   
*. Correlation is significant at the 0.05 level (2-tailed). 
  
The results of data analysis showed an existence of a positive relationship 
between number of medication and major drug-drug, moderate drug-drug, major drug-
disease and moderate drug-disease interactions (r = 0.240, p = 0.000; r = .596, p = 
0.000; r = 464, p = 0.000; r = 669, p = 0.000, respectively) (table 6). Therefore, the 
findings were significant. However, the Pearson correlations (r = -0.032, -0.059, 0.39, -
0.054) (table 6) did not depict significant relationship between age and major drug-drug, 
moderate drug-drug, major drug-disease, and moderate drug-disease interactions. 
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Table 7 
Summary of Regression Analysis using Age and Total Number of Medications as 
Independent Variables and Major drug-drug, Moderate drug-drug, Major drug-disease, 
and Moderate drug-disease as Dependent Variables 
 
 ANOVA 
MODEL 
Sum of 
Squares 
df Mean 
Square 
F Sig.  R R
2
  Adj
. R
2
 
Std. 
Erro
r of 
Est. 
Major 
Drug-
Drug 
Regression           18.906           2 9.453     7.678     .001  .243 .059 .051 1.110 
Residual            300.414        244 1.231       
Total            319.320        246        
Mod. 
Drug-
Drug 
Regression         640.661           2 320.305     68.823     .000  .601 .361 .355 2.157 
Residual            1135.584        244 4.654       
Total            1776.194        246        
Major 
Drug-
Disease 
Regression 594.546      2 297.273 33.629 .000 .465 .216 .210 2.973 
Residual 2156.887 244 8.840       
Total 2751.433 246        
Mod. 
Drug-
Disease 
Regression 88755.286 2 44377.64 101.05 .000 .673 .453 .449 20.96 
Residual 107157.094 244 439.168       
Total 195912.381 246        
           
 
The results of the regression analysis also consistently revealed a positive 
correlation between the number of medications and the severity levels of drug-drug or 
drug-disease interactions. The results showed that as the number of medication increased, 
the severity level of each interaction increased. The number of medications had the 
strongest effect on moderate drug-drug and moderate drug-disease interactions, 
explaining 36.1% (r²= .0361) and 45.3% (r²= .453) of the variations respectively. 
 However, while the number of medications did have a positive correlation with 
major drug-drug/drug-disease interactions, the effects were not very strong, explaining 
only 5.9% (r²= .059) and 22.0% (r²= .216) of the variations respectively (table 7). Again, 
age showed no relationship with all severity levels of drug-drug and drug-disease 
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interactions throughout the analysis. This was unexpected because according to previous 
study, advanced in age increases the potential of drug-drug interactions due to age 
physiologic changes (Cusack, B.J., 2004). Therefore, additional study is needed to 
understand this unusual occurrence. 
Evaluation 
The evaluation of this study was done in terms of its implications to clinical 
practice and social change. This study showed no relationship between age and the 
various severity levels of drug-drug/drug-disease interactions as one would expect and as 
found in literature. Therefore further research is needed to explore why no relationship 
exist between age and drug-drug/drug-disease interactions in elderly population aged 65 
years and older. Another profound result of this study that needs further research is the 
existence of polypharmacy without any corresponding increase in drug-drug/drug-disease 
interactions.  A number of unusual cases in the data showed the existence of 
polypharmacy without any or very few corresponding increase in the number of various 
interactions as one would expect. For example, a 76 y/o female with 10 medications and 
a 75 y/o female with eight medications resulted in zero alerts which mean zero drug-drug 
and zero drug-disease interactions (Appendix B).  
Polypharmacy in elderly has remained a major problem for NP practice. 
Therefore, the ability to utilize health information technology to determine the 
association between the number of medications and the severity of drug-drug and drug-
disease interactions may guide the NP in quality improvement initiative planning that 
may chart the course of change in the way providers prescribe to this population. For 
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example, the results can be used in development of a toolkit to assist prescribers to know 
which classes of medications to be eliminated in elderly or which combination of 
medications that should not be prescribed to this population. The process of completing 
this study has also exposed some organizational factors such as time constraint and 
demand for efficiency that sometimes act as barriers to full utilization of the available 
health information technology (HIT) in improving quality of care. These two factors 
require an organizational approach and a transformative leadership to chart the course for 
change. NPs should take the leadership role in implementing changes in their 
organizations as they are in a unique position to provide leadership in the evaluation of 
the health information system and employ collaborative and leadership skills to create 
change in the prescribing culture of clinician that has proven to be detrimental to the 
elderly population.  
Conclusion 
The objective of this study was to determine the relationship between the total 
number of medication taken by the elderly aged 65 and older and the severity of drug-
drug interactions and drug-disease interactions by utilizing the EMR automated trigger 
system which has the capacity to alert clinicians of the severity of these interactions. The 
findings of this study are similar to other studies revealing the association between 
increased number of medications and drug-drug/drug-disease interactions. This study 
therefore has added to research knowledge on polypharmacy by showing a positive 
correlation between the number of medications and the severity level of each interaction. 
Therefore HIT with it innovative capabilities such as the EMR automated trigger system 
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can assist clinicians in eliminating medications with potential adverse events, thereby 
decreasing polypharmacy at the point-of-care if fully utilized as it was intended. 
Dissemination 
My plan for dissemination this study is to have either a Poster or Podium 
Presentation during the AANP National Conference likely in 2017. My initial plan was to 
have a poster presentation during the AANP 2016 national conference at San Antonio, 
Texas in June. This is no longer possible as I could not meet the date line for abstract 
submission. AANP conference has offered novice and seasoned researchers alike a wider 
forum to showcase their work and to network with colleagues in fostering professional 
growth. Finding the right medium to disseminate research findings is always as important 
as the research itself. Dissemination of my DNP project is essential for development as a 
scholar-practitioner and a nurse leader. Being able to contribute to nursing knowledge 
through dissemination of my DNP project to a wider audience is crucial for my 
professional development. 
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Appendices 
Appendix A: Sample Data Collection Sheet 
Sample of data collection sheet 
 
Chart # Age Gender Total # 
 
DD 
  
DS 
 
   
of med 
 
Major Moderate Major Moderate 
     
(red) (orange) 
 
(red) (orange) 
1 75 M 14 
 
1 1 
 
14 28 
2 65 F 10 
 
2 8 
 
1 10 
3 
         4 
         5 
         6 
         7 
         8 
         9 
         10 
          
Key: DD= drug-drug interactions; DS= drug-disease interactions 
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Appendix B: Data Collection Form (N= 247) 
Age Gender 
Total# of 
med DD_Red DD_Orange DS_Red DS_Orange Gender1 
 
72 F 3 0 11 0 9 1 
 
73 F 4 2 6 0 0 1 
 
65 F 4 1 1 0 0 1 
 
80 F 7 0 0 0 0 1 
 
67 F 4 0 0 0 0 1 
 
78 M 2 0 0 0 0 0 
 
70 F 2 2 2 0 9 1 
 
78 F 23 2 10 2 83 1 
 
73 F 17 0 0 11 51 1 
 
81 M 7 0 0 1 2 0 
 
78 M 2 0 0 0 0 0 
 
79 F 3 0 1 0 0 1 
 
71 F 5 0 0 0 2 1 
 
82 F 8 0 1 0 0 1 
 
76 F 10 0 0 0 0 1 
 
69 F 9 0 0 0 1 1 
 
71 M 2 0 0 0 0 0 
 
70 M 3 0 0 0 0 0 
 
76 F 17 1 0 2 38 1 
 
87 M 6 0 0 0 0 0 
 
69 F 2 0 0 0 11 1 
 
75 F 5 0 3 5 52 1 
 
70 F 14 2 6 0 29 1 
 
85 M 6 0 0 0 0 0 
 
76 F 13 0 0 0 0 1 
 
78 F 13 0 1 5 45 1 
 
76 F 22 0 0 0 0 1 
 
68 F 5 0 0 0 0 1 
 
85 F 13 6 1 10 35 1 
 
70 F 4 0 0 0 0 1 
 
73 M 6 0 0 0 0 0 
 
66 M 4 0 0 0 0 0 
 
67 M 5 0 1 0 14 0 
 
67 F 2 0 0 0 0 1 
 
73 F 2 0 0 0 1 1 
 
71 
 
72 M 2 0 0 0 0 0 
 
84 F 18 0 0 0 2 1 
 
86 M 7 0 0 0 0 0 
 
73 F 8 0 0 0 0 1 
 
77 F 4 0 0 0 0 1 
 
75 F 5 0 0 0 0 1 
 
71 F 3 0 0 0 7 1 
 
67 F 9 1 0 1 14 1 
 
77 F 7 1 2 2 8 1 
 
87 M 10 0 1 0 6 0 
 
66 F 8 1 4 0 2 1 
 
72 F 2 0 0 0 0 1 
 
66 M 5 0 0 0 36 0 
 
69 M 3 0 6 0 1 0 
 
69 M 5 0 1 0 15 0 
 
66 M 5 0 2 0 0 0 
 
67 F 4 0 0 0 0 1 
 
86 M 8 0 1 0 23 0 
 
74 F 10 0 1 0 0 1 
 
69 F 11 0 0 0 0 1 
 
88 F 15 0 0 0 17 1 
 
67 F 8 1 0 1 14 1 
 
65 F 12 0 2 0 0 1 
 
74 F 10 1 4 0 25 1 
 
84 F 11 2 0 0 15 1 
 
68 M 6 0 0 0 0 0 
 
69 F 10 1 1 0 36 1 
 
84 M 12 4 2 7 58 0 
 
66 F 11 0 0 0 0 1 
 
84 M 6 4 0 0 23 0 
 
85 F 5 0 0 0 0 1 
 
86 F 4 0 0 0 0 1 
 
68 F 13 0 4 1 110 1 
 
87 M 5 0 2 0 4 0 
 
65 F 27 0 6 12 144 1 
 
67 F 14 0 4 0 21 1 
 
80 F 7 0 0 0 18 1 
 
67 F 2 0 0 0 1 1 
 
90 F 3 0 0 1 13 1 
 
69 F 8 0 2 0 2 1 
 
72 
 
67 F 5 0 0 0 3 1 
 
71 F 8 0 2 0 13 1 
 
70 F 7 0 3 0 29 1 
 
74 F 7 0 0 0 0 1 
 
88 F 6 0 2 0 2 1 
 
66 F 5 0 1 0 5 1 
 
84 F 20 2 6 4 54 1 
 
67 F 4 0 0 0 0 1 
 
76 F 18 1 6 1 74 1 
 
76 M 4 0 0 0 3 0 
 
83 F 5 0 0 0 20 1 
 
69 M 3 0 0 0 0 0 
 
69 F 3 0 0 0 2 1 
 
70 M 2 0 1 0 26 0 
 
70 F 8 1 3 0 43 1 
 
85 M 3 0 0 0 0 0 
 
89 F 13 0 5 5 9 1 
 
78 F 4 0 2 7 15 1 
 
66 M 7 2 5 0 12 0 
 
92 F 5 0 0 0 6 1 
 
89 F 2 0 0 0 0 1 
 
69 M 10 0 5 1 14 0 
 
66 F 7 0 10 12 11 1 
 
71 F 4 0 0 0 10 1 
 
71 M 2 0 0 0 10 0 
 
76 M 8 0 0 0 0 0 
 
72 F 5 0 1 0 0 1 
 
73 M 10 4 7 0 0 0 
 
65 M 3 1 0 0 8 0 
 
65 F 6 0 0 0 5 1 
 
72 F 2 0 0 0 2 1 
 
79 F 8 1 1 0 32 1 
 
71 F 17 2 5 0 0 1 
 
72 F 12 1 4 0 12 1 
 
73 F 10 0 1 9 62 1 
 
66 F 5 0 0 0 32 1 
 
66 M 9 0 1 1 61 0 
 
72 F 2 0 0 0 0 1 
 
68 M 13 1 4 5 108 0 
 
70 F 7 0 0 0 0 1 
 
73 
 
73 F 10 1 8 3 63 1 
 
66 F 9 0 1 0 8 1 
 
73 M 4 0 2 0 2 0 
 
66 F 3 0 0 0 1 1 
 
71 F 5 0 0 2 0 1 
 
68 F 3 0 0 0 1 1 
 
77 F 8 0 4 0 22 1 
 
83 F 8 0 7 2 43 1 
 
69 M 11 0 1 1 56 0 
 
88 F 2 0 0 0 13 1 
 
71 F 13 2 14 16 67 1 
 
81 F 8 0 4 0 24 1 
 
68 M 3 0 0 1 0 0 
 
66 F 22 0 4 8 53 1 
 
83 F 15 0 3 5 50 1 
 
72 F 3 0 0 0 5 1 
 
79 F 13 1 6 3 32 1 
 
83 F 2 0 0 0 0 1 
 
93 F 12 0 4 2 13 1 
 
66 F 12 0 6 2 54 1 
 
66 M 3 0 0 0 2 0 
 
80 F 2 0 0 0 0 1 
 
71 F 24 1 10 2 82 1 
 
67 F 13 0 2 0 38 1 
 
65 F 8 0 0 0 4 1 
 
69 F 2 0 0 0 10 1 
 
80 F 16 0 13 5 88 1 
 
66 M 5 0 0 0 0 0 
 
70 F 3 0 0 0 5 1 
 
75 F 3 0 1 0 12 1 
 
79 M 23 0 8 12 83 0 
 
76 M 4 1 2 0 0 0 
 
76 F 14 1 4 5 57 1 
 
78 F 3 0 0 0 7 1 
 
76 F 4 0 0 0 3 1 
 
73 F 4 0 2 0 2 1 
 
65 F 4 0 0 0 2 1 
 
65 F 4 0 3 2 10 1 
 
77 F 4 0 0 0 4 1 
 
75 F 8 0 6 0 16 1 
 
74 
 
68 F 5 2 0 0 14 1 
 
83 F 7 1 2 0 37 1 
 
89 F 5 0 1 0 24 1 
 
68 F 23 1 8 5 113 1 
 
74 F 2 0 0 0 0 1 
 
78 F 2 0 0 0 0 1 
 
95 F 6 1 2 0 2 1 
 
66 F 9 0 1 0 4 1 
 
72 F 5 0 0 0 16 1 
 
67 F 2 0 0 0 20 1 
 
74 M 7 0 1 0 0 0 
 
92 F 10 0 2 16 38 1 
 
70 F 5 0 1 0 22 1 
 
77 M 7 1 4 0 22 0 
 
66 M 2 0 0 0 1 0 
 
66 M 11 0 3 11 17 0 
 
87 M 4 0 0 0 0 0 
 
69 F 4 0 0 0 0 1 
 
87 F 5 0 0 0 19 1 
 
82 F 9 0 4 0 2 1 
 
67 F 11 0 2 0 5 1 
 
72 F 12 0 7 0 0 1 
 
78 F 17 2 9 0 7 1 
 
68 M 10 3 6 0 41 0 
 
66 M 2 0 0 0 0 0 
 
65 F 5 0 2 3 56 1 
 
73 M 2 0 0 0 0 0 
 
73 M 13 0 4 2 50 0 
 
88 F 2 0 0 0 1 1 
 
71 F 3 0 0 0 25 1 
 
69 F 4 0 1 0 0 1 
 
75 F 8 0 0 0 0 1 
 
98 F 2 0 0 0 0 1 
 
85 F 3 0 1 0 14 1 
 
66 F 2 0 0 0 2 1 
 
72 M 10 0 4 14 50 0 
 
74 M 5 0 0 0 43 0 
 
66 F 10 7 3 0 70 1 
 
75 F 3 0 0 0 20 1 
 
68 M 6 10 6 0 13 0 
 
75 
 
73 M 11 0 8 3 30 0 
 
83 F 14 0 3 0 63 1 
 
66 F 22 5 8 20 164 1 
 
77 M 5 0 1 2 6 0 
 
68 F 18 0 6 0 20 1 
 
74 M 18 0 5 2 48 0 
 
85 F 19 0 5 12 93 1 
 
74 F 12 4 7 2 56 1 
 
70 F 8 0 4 0 11 1 
 
67 M 6 0 0 0 29 0 
 
83 M 4 0 0 0 10 0 
 
85 F 7 0 3 0 17 1 
 
76 M 17 0 5 14 177 0 
 
65 M 2 0 0 1 0 0 
 
66 F 3 0 1 0 6 1 
 
86 F 8 1 0 0 14 1 
 
66 F 4 0 0 0 0 1 
 
75 M 2 0 0 0 0 0 
 
82 F 13 0 0 0 30 1 
 
88 F 3 0 0 0 2 1 
 
90 F 5 0 1 0 2 1 
 
72 F 3 0 0 0 1 1 
 
77 M 7 0 2 0 0 0 
 
66 F 17 1 8 2 28 1 
 
65 F 7 0 1 2 35 1 
 
83 F 10 1 5 12 28 1 
 
75 M 4 1 1 2 16 0 
 
70 F 2 0 0 0 0 1 
 
74 F 4 0 0 0 2 1 
 
68 M 2 0 2 0 0 0 
 
91 F 14 0 2 0 28 1 
 
78 F 7 0 0 1 17 1 
 
83 F 6 0 2 0 12 1 
 
82 M 7 0 2 0 5 0 
 
78 M 3 0 0 0 11 0 
 
77 F 3 0 0 0 0 1 
 
71 F 8 0 3 12 58 1 
 
66 F 2 0 0 0 0 1 
 
68 F 10 1 5 1 9 1 
 
70 M 10 0 1 0 15 0 
 
76 
 
76 F 3 0 0 0 1 1 
 
65 M 3 0 0 0 0 0 
 
80 M 8 2 3 0 7 0 
 
66 F 7 0 2 0 33 1 
 
83 M 5 0 0 3 23 0 
 
77 M 3 0 0 10 3 0 
 
89 F 3 0 0 0 0 1 
 
67 F 16 0 0 0 80 1 
 
88 F 5 0 0 2 10 1 
 
70 F 7 0 4 0 0 1 
 
79 F 8 0 0 0 48 1 
 
66 F 3 0 0 0 27 1 
 Key: DD= drug-drug interactions; DS= drug-disease interactions 
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Appendix C: SPSS Output Correlation 
i. Major drug-drug interactions 
Correlations 
 
Age of patient 
Total number of 
medications 
Major drug-
drug 
Recoded 
gender 
Age of patient Pearson 
Correlation 
1 .029 -.032 .051 
Sig. (2-tailed)  .652 .620 .426 
N 247 247 247 247 
Total number of 
medications 
Pearson 
Correlation 
.029 1 .240
**
 .150
*
 
Sig. (2-tailed) .652  .000 .019 
N 247 247 247 247 
Major drug-drug Pearson 
Correlation 
-.032 .240
**
 1 -.044 
Sig. (2-tailed) .620 .000  .495 
N 247 247 247 247 
Recoded gender Pearson 
Correlation 
.051 .150
*
 -.044 1 
Sig. (2-tailed) .426 .019 .495  
N 247 247 247 247 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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ii. Moderate drug-drug interaction 
Correlations 
 
Age of 
patient 
Total number of 
medications 
Recoded 
gender 
Moderate 
drug-drug 
Age of patient Pearson 
Correlation 
1 .029 .051 -.059 
Sig. (2-tailed)  .652 .426 .357 
N 247 247 247 247 
Total number of 
medications 
Pearson 
Correlation 
.029 1 .150
*
 .596
**
 
Sig. (2-tailed) .652  .019 .000 
N 247 247 247 247 
Recoded gender Pearson 
Correlation 
.051 .150
*
 1 .067 
Sig. (2-tailed) .426 .019  .291 
N 247 247 247 247 
Moderate drug-drug Pearson 
Correlation 
-.059 .596
**
 .067 1 
Sig. (2-tailed) .357 .000 .291  
N 247 247 247 247 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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iii. Major drug-disease interaction 
Correlations 
 
Age of patient 
Total number of 
medications 
Recoded 
gender 
Major drug 
disease 
Age of patient Pearson 
Correlation 
1 .029 .051 .039 
Sig. (2-tailed)  .652 .426 .543 
N 247 247 247 247 
Total number of 
medications 
Pearson 
Correlation 
.029 1 .150
*
 .464
**
 
Sig. (2-tailed) .652  .019 .000 
N 247 247 247 247 
Recoded gender Pearson 
Correlation 
.051 .150
*
 1 .006 
Sig. (2-tailed) .426 .019  .928 
N 247 247 247 247 
Major drug disease Pearson 
Correlation 
.039 .464
**
 .006 1 
Sig. (2-tailed) .543 .000 .928  
N 247 247 247 247 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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iv. Moderate Drug-Drug Correlation 
Correlations 
 
Age of patient 
Total number 
of medications 
Recoded 
gender 
Moderate 
drug disease 
Age of patient Pearson 
Correlation 
1 .029 .051 -.054 
Sig. (2-tailed)  .652 .426 .398 
N 247 247 247 247 
Total number of 
medications 
Pearson 
Correlation 
.029 1 .150
*
 .669
**
 
Sig. (2-tailed) .652  .019 .000 
N 247 247 247 247 
Recoded gender Pearson 
Correlation 
.051 .150
*
 1 .047 
Sig. (2-tailed) .426 .019  .461 
N 247 247 247 247 
Moderate drug disease Pearson 
Correlation 
-.054 .669
**
 .047 1 
Sig. (2-tailed) .398 .000 .461  
N 247 247 247 247 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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APPENDIX D: SPSS REGRESSIONS OUTPUT 
i. Major Drug-Drug Interactions 
 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
1 .256
a
 0.065 0.054 1.108 
a. Predictors: (Constant), Recoded gender, Age of patient, Total number of medications 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 20.886 3 6.962 5.669 .001
a
 
Residual 298.434 243 1.228   
Total 319.320 246    
a. Predictors: (Constant), Recoded gender, Age of patient, Total number of medications 
b. Dependent Variable: Major drug-drug 
 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) .521 .704  .739 .460 
Age of patient -.005 .009 -.035 -.563 .574 
Total number of medications .056 .014 .253 4.035 .000 
Recoded gender -.200 .158 -.080 -1.270 .205 
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Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) .521 .704  .739 .460 
Age of patient -.005 .009 -.035 -.563 .574 
Total number of medications .056 .014 .253 4.035 .000 
Recoded gender -.200 .158 -.080 -1.270 .205 
a. Dependent Variable: Major drug-drug 
 
 
ii. Major Drug-Disease Interactions 
 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
1 .469a 0.220 0.211 2.971 
a. Predictors: (Constant), Recoded gender, Age of patient, Total number of medications 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 606.426 3 202.142 22.900 .000
a
 
Residual 2145.007 243 8.827   
Total 2751.433 246    
a. Predictors: (Constant), Recoded gender, Age of patient, Total number of medications 
b. Dependent Variable: Major drug disease 
 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) -1.517 1.887  -.804 .422 
Age of patient .013 .025 .029 .504 .615 
Total number of medications .306 .037 .473 8.260 .000 
Recoded gender -.491 .423 -.067 -1.160 .247 
a. Dependent Variable: Major drug disease 
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iii. Moderate Drug-Drug Interactions 
 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
1 .601a 0.361 0.353 2.161 
a. Predictors: (Constant), Recoded gender, Age of patient, Total number of medications 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 641.213 3 213.738 45.761 .000
a
 
Residual 1134.982 243 4.671   
Total 1776.194 246    
a. Predictors: (Constant), Recoded gender, Age of patient, Total number of medications 
b. Dependent Variable: Moderate drug-drug 
 
Coefficientsa 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 1.580 1.373  1.151 .251 
Age of patient -.027 .018 -.075 -1.465 .144 
Total number of medications .312 .027 .601 11.579 .000 
Recoded gender -.110 .308 -.019 -.359 .720 
a. Dependent Variable: Moderate drug-drug 
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iv. Moderate Drug-Disease Interactions 
 
 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
1 .675a 0.456 0.449 20.951 
a. Predictors: (Constant), Recoded gender, Age of patient, Total number of medications 
 
 
ANOVA
b
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 89249.503 3 29749.834 67.776 .000
a
 
Residual 106662.877 243 438.942   
Total 195912.381 246    
a. Predictors: (Constant), Recoded gender, Age of patient, Total number of medications 
b. Dependent Variable: Moderate drug disease 
 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 13.198 13.310  .992 .322 
Age of patient -.264 .176 -.071 -1.497 .136 
Total number of medications 3.705 .261 .679 14.174 .000 
Recoded gender -3.165 2.982 -.051 -1.061 .290 
a. Dependent Variable: Moderate drug disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
